文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

鼻内 mRNA-LNP 疫苗接种可保护仓鼠免受 SARS-CoV-2 感染。

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection.

机构信息

Moderna Inc., Cambridge, MA, USA.

Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.

出版信息

Sci Adv. 2023 Sep 22;9(38):eadh1655. doi: 10.1126/sciadv.adh1655.

DOI:10.1126/sciadv.adh1655
PMID:37738334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10516494/
Abstract

Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.

摘要

鼻腔接种代表了一种很有前途的方法，通过在呼吸道中引发黏膜免疫反应来预防呼吸道病原体引起的疾病，这种反应可以作为感染和传播的早期屏障。本研究调查了鼻腔内给予信使 RNA（mRNA）-脂质纳米颗粒（LNP）包裹疫苗对叙利亚金黄地鼠严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的免疫原性和保护效果。鼻腔内 mRNA-LNP 疫苗接种系统地诱导了刺突特异性结合[免疫球蛋白 G（IgG）和 IgA]和中和抗体。鼻腔内接种疫苗的仓鼠在 SARS-CoV-2 攻击后呼吸道中的病毒载量也降低，肺部病理减少，体重减轻也得到了预防。总之，这项研究证明了鼻腔内给予的 mRNA-LNP 疫苗具有成功的免疫原性和针对呼吸道病毒感染的保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/929d27fbdabe/sciadv.adh1655-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/e6636ec7dcbc/sciadv.adh1655-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/6062ed2c8748/sciadv.adh1655-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/9339db4f99d4/sciadv.adh1655-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/28e13d49415e/sciadv.adh1655-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/0b22e4ce8ce0/sciadv.adh1655-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/73bd95019e5e/sciadv.adh1655-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/929d27fbdabe/sciadv.adh1655-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/e6636ec7dcbc/sciadv.adh1655-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/6062ed2c8748/sciadv.adh1655-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/9339db4f99d4/sciadv.adh1655-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/28e13d49415e/sciadv.adh1655-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/0b22e4ce8ce0/sciadv.adh1655-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/73bd95019e5e/sciadv.adh1655-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27c2/10516494/929d27fbdabe/sciadv.adh1655-f7.jpg

相似文献

[1]
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection.

Sci Adv. 2023-9-22

[2]
Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.

Vaccine. 2024-1-12

[3]
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.

Proc Natl Acad Sci U S A. 2022-6-14

[4]
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.

Vaccine. 2022-9-29

[5]
An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters.

Sci Rep. 2023-7-26

[6]
Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.

Microbiol Spectr. 2024-3-5

[7]
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.

EBioMedicine. 2022-8

[8]
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.

PLoS One. 2022

[9]
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.

Cell Host Microbe. 2021-2-10

[10]
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.

mBio. 2021-10-26

引用本文的文献

[1]
Systemic and Mucosal Humoral Immune Responses to Lumazine Synthase 60-mer Nanoparticle SARS-CoV-2 Vaccines.

Vaccines (Basel). 2025-7-23

[2]
Intranasal mRNA vaccines: Targeting mucosal immunity through optimized delivery.

Mol Ther Nucleic Acids. 2025-8-8

[3]
Intranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease.

NPJ Vaccines. 2025-7-4

[4]
The interplay between host immunity and infection.

mBio. 2025-8-13

[5]
Recent advances on coxsackievirus A6 vaccine research.

Front Immunol. 2025-6-6

[6]
Deconvolution of cargo delivery and immunogenicity following intranasal delivery of mRNA lipid nanoparticle vaccines.

Mol Ther Nucleic Acids. 2025-4-24

[7]
Laminar fluid ejection device enables high yield and preservation of mRNA and SaRNA LNP formulations.

Sci Rep. 2025-5-27

[8]
mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 variant in the lower and upper respiratory tract.

bioRxiv. 2025-4-29

[9]
Nasal vaccines for respiratory infections.

Nature. 2025-5

[10]
Beyond COVID-19: the promise of next-generation coronavirus vaccines.

Npj Viruses. 2024-8-22

本文引用的文献

[1]
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.

EBioMedicine. 2022-11

[2]
China and India approve nasal COVID vaccines - are they a game changer?

Nature. 2022-9

[3]
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2.

NPJ Vaccines. 2022-7-29

[4]
Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity.

Sci Transl Med. 2022-7-20

[5]
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.

Sci Immunol. 2022-10-28

[6]
Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects.

Curr Opin Immunol. 2022-8

[7]
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines.

Mucosal Immunol. 2022-4

[8]
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters.

Med. 2022-4-8

[9]
Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge.

NPJ Vaccines. 2022-3-14

[10]
Intranasal COVID-19 vaccines: From bench to bed.

EBioMedicine. 2022-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索